Aug 06, 2020 4:01 pm EDT Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 30, 2020 9:15 am EDT Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
May 26, 2020 9:25 am EDT Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 14, 2020 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020 4:30 pm EDT Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13, 2020 7:00 am EDT Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
Apr 29, 2020 9:15 am EDT New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
Apr 13, 2020 9:00 am EDT Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
Apr 03, 2020 8:00 am EDT Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy